French pharma major Sanofi (Euronext: SAN) has entered into a new global collaboration with long-time partner US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology, an area of research that is attracting ever more attention, with Sanofi committing an initial $2.17 billion to the deal.
As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase I testing, and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs.
Sanofi’s existing collaboration with Regeneron has already delivered the potential blockbuster cholesterol lowerer Praluent (alirocumab), which last Friday gained US Food and Drug Administration approval, as well as a favorable opinion from the European Medicines Agency’s advisory committee.
Regeneron to get $640 million upfront
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze